[go: up one dir, main page]

WO2013036610A3 - Compositions comprising mg53 and methods for the treatment and prevention of airway injury - Google Patents

Compositions comprising mg53 and methods for the treatment and prevention of airway injury Download PDF

Info

Publication number
WO2013036610A3
WO2013036610A3 PCT/US2012/053920 US2012053920W WO2013036610A3 WO 2013036610 A3 WO2013036610 A3 WO 2013036610A3 US 2012053920 W US2012053920 W US 2012053920W WO 2013036610 A3 WO2013036610 A3 WO 2013036610A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
methods
prevention
airway injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/053920
Other languages
French (fr)
Other versions
WO2013036610A2 (en
Inventor
Jianjie Ma
Noah Weisleder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Priority to US14/343,560 priority Critical patent/US20150110778A1/en
Priority to EP12829354.5A priority patent/EP2753363A4/en
Priority to CN201280056362.1A priority patent/CN104066452A/en
Publication of WO2013036610A2 publication Critical patent/WO2013036610A2/en
Publication of WO2013036610A3 publication Critical patent/WO2013036610A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof.
PCT/US2012/053920 2006-07-11 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury Ceased WO2013036610A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/343,560 US20150110778A1 (en) 2006-07-11 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury
EP12829354.5A EP2753363A4 (en) 2011-09-07 2012-09-06 COMPOSITIONS COMPRISING MG53 AND METHODS FOR TREATING AND PREVENTING INJURIES AT THE RESPIRATORY LEVEL
CN201280056362.1A CN104066452A (en) 2011-09-07 2012-09-06 MG53-containing compositions and methods for treating and preventing airway injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161531708P 2011-09-07 2011-09-07
US61/531,708 2011-09-07

Publications (2)

Publication Number Publication Date
WO2013036610A2 WO2013036610A2 (en) 2013-03-14
WO2013036610A3 true WO2013036610A3 (en) 2013-05-02

Family

ID=47832768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/053920 Ceased WO2013036610A2 (en) 2006-07-11 2012-09-06 Compositions comprising mg53 and methods for the treatment and prevention of airway injury

Country Status (3)

Country Link
EP (1) EP2753363A4 (en)
CN (1) CN104066452A (en)
WO (1) WO2013036610A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306296B2 (en) 2016-08-01 2022-04-19 Hope Medicine (Nanjing) Co., Ltd. MG53 mutants, methods of making the same, and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266551B (en) * 2016-04-06 2021-03-05 牡丹江友搏药业有限责任公司 MG53 mutant and preparation method and application thereof
CN107987147B (en) * 2016-10-26 2024-07-05 牡丹江友搏药业有限责任公司 MG53 polymer preparation method and application thereof
CN110753557B (en) * 2017-03-22 2024-03-22 神济昌华(北京)生物科技有限公司 TRIM72 uses ubiquitinated FUS protein mutants as potential therapeutic targets for ALS
CN107629123B (en) * 2017-09-07 2020-08-25 北京大学 Nano antibody for resisting MG53 protein and application
CN113474011A (en) * 2018-12-07 2021-10-01 俄亥俄州立创新基金会 Compositions and methods for promoting corneal tissue repair
WO2020256905A1 (en) 2019-06-17 2020-12-24 Trim-Edicine, Inc. Composition for and method of treating hepatic tissue injury
WO2021015894A1 (en) * 2019-07-25 2021-01-28 Trim-Edicine, Inc. Composition for and method of improving tissue performance
CN115835877A (en) 2020-04-14 2023-03-21 俄亥俄州立创新基金会 Prevention and treatment of organ failure caused by viral infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US20090075875A1 (en) * 2006-10-03 2009-03-19 Stanley Hoffman Protection against lung fibrosis by up-regulating the function or expression of caveolin-1
US20110202033A1 (en) * 2006-07-11 2011-08-18 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471809B1 (en) * 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
KR101413005B1 (en) * 2007-12-04 2014-07-02 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Compositions and methods to modulate cell membrane resealing
CN101797375B (en) * 2009-12-02 2013-01-23 北京大学 Application of MG53 protein for preventing and/or treating myocardial ischemia/reperfusion injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
US20110202033A1 (en) * 2006-07-11 2011-08-18 Noah Weisleder Compositions and methods for the treatment and prevention of cardiac ischemic injury
US20090075875A1 (en) * 2006-10-03 2009-03-19 Stanley Hoffman Protection against lung fibrosis by up-regulating the function or expression of caveolin-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2753363A4 *
ZHU, H. ET AL.: "Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair", JBC, vol. 286, no. 15, 15 April 2011 (2011-04-15), pages 12820 - 12824, XP055066140 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306296B2 (en) 2016-08-01 2022-04-19 Hope Medicine (Nanjing) Co., Ltd. MG53 mutants, methods of making the same, and uses thereof

Also Published As

Publication number Publication date
EP2753363A2 (en) 2014-07-16
CN104066452A (en) 2014-09-24
WO2013036610A2 (en) 2013-03-14
EP2753363A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IN2014DN09173A (en)
GB2503066B8 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EP2440209A4 (en) Compositions and methods for the prevention and treatment of heart failure
HUE041553T2 (en) Methods and compositions for the treatment of monogenic diseases
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
WO2012047951A3 (en) Human lung stem cells and uses thereof
IL225668A (en) Formulations for the treatment of disorders of the upper respiratory tract
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
IL225793A0 (en) Methods and compositions for the treatment of insulin-associated medical conditions
IL219579A0 (en) Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
WO2013117744A3 (en) Methods of treating fibrosis
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
WO2013059233A3 (en) Thermoresponsive compositions for dermatological use and methods thereof
WO2012024583A3 (en) Oxysterol compounds
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2014203074A3 (en) Use of unacylated ghrelin, fragments and analogs thereof as antioxidant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829354

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012829354

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14343560

Country of ref document: US